Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B.
Matrix metalloproteinase (MMPs) enzymes are implicated in matrix remodelling during proliferative inflammatory processes including wound healing. We report here synergistic upregulation of MMP-9 protein and mRNA by platelet-derived growth factor (PDGF) or basic fibroblast growth factor (bFGF) in combination with interleukin-1alpha (IL-1alpha) or tumour necrosis factor-alpha (TNF-alpha) in primary rabbit and human dermal fibroblasts. The synergistic interaction between growth factors and cytokines implies that basement membrane remodelling is maximal physiologically when both are present together. The signalling pathways mediating this synergistic regulation are not understood, although analysis of the MMP-9 promoter has identified an essential proximal AP-1 element and an upstream nuclear factor kappa-B (NF-kappaB) site. Using electromobility shift assays, binding to the AP-1 site was only slightly increased by growth factors and cytokines. NF-kappaB binding was rapidly induced by IL-1alpha or TNF-alpha but was neither induced nor potentiated by bFGF or PDGF. Neither AP-1 nor NF-kappaB was therefore sufficient on its own for synergistic regulation. Using a recently developed adenovirus that overexpresses the inhibitory subunit, IkappaB alpha, we demonstrated an absolute requirement for NF-kappaB in upregulation of MMP-9. Activation of NF-kappaB binding by inflammatory cytokines was therefore necessary but not sufficient for synergistic upregulation of MMP-9.
Bristol Heart Institute, University of Bristol, Bristol Royal Infirmary, UK.
M
M
Bond
R P
RP
Fabunmi
A H
AH
Baker
A C
AC
Newby
D000818:Animals; D002478:Cells, Cultured; D017364:Collagenases / Q000096:biosynthesis* / Q000187:drug effects / Q000378:metabolism; D016207:Cytokines / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000502:physiology; D004338:Drug Combinations; D004357:Drug Synergism; D004591:Electrophoresis, Polyacrylamide Gel; D005347:Fibroblasts; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D020672:I-kappa B Proteins; D007249:Inflammation / Q000201:enzymology; D020780:Matrix Metalloproteinase 9; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology*; D011817:Rabbits; D018808:Transcription Factor AP-1 / Q000502:physiology; D015854:Up-Regulation / Q000187:drug effects
D016207:Cytokines; D004268:DNA-Binding Proteins; D004338:Drug Combinations; D006133:Growth Substances; D020672:I-kappa B Proteins; D016328:NF-kappa B; C000606204:NFKBIA protein, human; D018808:Transcription Factor AP-1; D000072000:NF-KappaB Inhibitor alpha; D017364:Collagenases; D020780:Matrix Metalloproteinase 9